Sterling Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Sterling Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.9K	Sell	1,930 -16	-0.8%	-$229	﹤0.01%	1868
2025 Q4	$27.7K	Buy	1,946 +1,271	+188%	+$12.5K	﹤0.01%	2060
2025 Q3	$5.32K	Buy	675 +2	+0.3%	+$14	﹤0.01%	2754
2025 Q2	$3.86K	Buy	673 +362	+116%	+$2.34K	﹤0.01%	2650
2025 Q1	$2.54K	Buy	311 +13	+4%	+$120	﹤0.01%	2498
2024 Q4	$2.81K	Hold	298	–	–	﹤0.01%	2671
2024 Q3	$3.18K	Buy	+298	New	+$3.25K	﹤0.01%	1967
2017 Q4	–	Sell	-14,455	Closed	-$218K	–	909
2017 Q3	$218K	Buy	+14,455	New	+$191K	﹤0.01%	874
2015 Q3	–	Sell	-13,664	Closed	-$193K	–	983
2015 Q2	$193K	Buy	+13,664	New	+$164K	﹤0.01%	854

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Sterling Capital Management's FOLD Position: Q1 2026 in Review

Sterling Capital Management reduced its Amicus Therapeutics (FOLD) stake by 0.82% in Q1 2026, selling an estimated $229 and leaving 1,930 shares worth $27.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1868.

Sterling Capital Management first reported a position in FOLD in Q2 2015 and has held it in 9 quarters since. The position peaked at $218K in Q3 2017. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Sterling Capital Management held 1,930 shares of Amicus Therapeutics worth $27.9K as of Q1 2026.
Sterling Capital Management sold 16 Amicus Therapeutics shares in Q1 2026, an estimated $229.
Amicus Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1868 holding.
Sterling Capital Management first reported a position in Amicus Therapeutics in Q2 2015 and has held it in 9 quarters since.
Sterling Capital Management's Amicus Therapeutics position peaked at $218K in Q3 2017.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.